Scarica l'app Stockscreener
2.01
6.94%
-0.15
Dopo l'orario di chiusura:
2.05
0.04
+1.99%
Precedente Chiudi:
$2.16
Aprire:
$2.15
Volume 24 ore:
68,403
Relative Volume:
0.83
Capitalizzazione di mercato:
$149.21M
Reddito:
-
Utile/perdita netta:
$-4.67M
Rapporto P/E:
-31.65
EPS:
-0.0635
Flusso di cassa netto:
-
1 W Prestazione:
-11.45%
1M Prestazione:
-4.29%
6M Prestazione:
-17.62%
1 anno Prestazione:
-96.35%
Intervallo 1D:
$1.965
$2.195
Intervallo di 1 settimana:
$1.965
$2.44
Portata 52W:
$1.43
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
Nome
Jyong Biotech Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Compare MENS vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
2.01 | 160.34M | 0 | -4.67M | 0 | -0.0635 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jyong Biotech Ltd Borsa (MENS) Ultime notizie
Jyong Biotech (MENS) Jumps 7.6% to $2.28, Closing in on Resistance at $2.39Throwback Trade - siam.in
Jyong Biotech Ltd. Ordinary Shares (NASDAQ: MENS) Share Price, MENS Stock News, MENS Share Price & Updates - kalkine.com.au
A plant-based drug developer will join a two-language online investor event Sept. 6 - Stock Titan
Jyong (MENS) Move: Gains 2.88% to Reach $2.14 on the Day; Current Setup: the Session Ends Within the Reported Technical Boundaries on the DayVolume Nodes - vinanet.vn
Jyong Biotech (MENS) Holds Flat at $2.1 as Shares Consolidate Between Key Support and Resistance LevelsLow Beta Factor - vinanet.vn
Jyong Biotech (MENS) Edges Up to $2.03, Holding a Tight Range Between Support and ResistanceDynamic Hedging - dars.gov.et
Jyong Biotech (MENS) Dips 0.98% to $2.03 as Biotech Stock Tests Range-Bound SupportIntraday Profile - vinanet.vn
Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships - Macau Business
Jyong Biotech Ltd (MENS) Institutional Confidence - TradingKey
Jyong Biotech Ltd (MENS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Jyong Biotech Ltd (MENS) Income Statement - TradingKey
Jyong Biotech Ltd (MENS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MENS|Jyong Biotech Ltd|Price:2.360|Chg%:-0.350 - TradingKey
Jyong Biotech Ltd (MENS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jyong Biotech Ltd (MENS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Jyong Biotech Ltd (MENS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jyong Biotech Ltd (MENS) Balance Sheet - TradingKey
Jyong Biotech Ltd (MENS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Jyong Biotech pursues global licensing partnerships for BPH drug By Investing.com - Investing.com Nigeria
Jyong Biotech targets $22B global BPH market wi... - Pluang
Jyong Biotech pursues global licensing partnerships for BPH drug - Investing.com
Jyong Biotech Ltd. Reaffirms Global Licensing Strategy for Botanical BPH Drug Candidate Botreso - Quiver Quantitative
Benign prostatic hyperplasia patients projected to reach 150M-156M by 2035 - Stock Titan
Jyong Biotech (MENS) Gains 3.88% as Positive Momentum Targets Key ResistanceFactor Momentum - Vinanet
Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Down 36.2% in June - MarketBeat
Jyong Biotech (MENS) Dips 1.3% as Stock Approaches Key Support at $2.16Value Area Low - vinanet.vn
Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention - Macau Business
Jyong Biotech presents drug candidate at BIO 2026 convention By Investing.com - Investing.com Nigeria
Jyong Biotech presents drug candidate at BIO 2026 convention - Investing.com
Jyong Biotech advances botanical drug Botreso® at BIO 2026, targeting global licensing for BPH treatment. - Pluang
Jyong Biotech (MENS) Retreats Over 5% as Key Support Test LoomsForce Index - dars.gov.et
Price to sales forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Enterprise value to EBIT forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Enterprise value to EBITDA forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Price to book forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Jyong Biotech Ltd. (MENS) Modest Gain Amidst Tight Trading RangeDefined Outcome ETF - DonanımHaber
Jyong Biotech Ltd (MENS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Number of shareholders of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Jyong Biotech Ltd (MENS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Certain Ordinary Shares of Jyong Biotech Ltd. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
JYONG BIOTECH LTD (MENS) Stock Chart - ChartMill
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview - digitalmore.co
Jyong Biotech outlines FDA approval path for botanical drug Botreso® targeting benign prostatic hyperplasia. - Pluang
Jyong Biotech (MENS) Remains Range-Bound as Price Consolidates Near SupportPut Flow Alert - The Legal Advocate
MENS - Finviz
Jyong Biotech Ltd. (MENS) Rises 2.36% as Stock Approaches Key ResistanceElliott Wave Count - dars.gov.et
Jyong Biotech Ltd. (MENS) Surges 3.37% as Buyers Defend Key Support LevelTake Profit Levels - The Legal Advocate
Jyong Biotech Ltd. (MENS) Shows Resilience: Uptick from Key Support ZoneImbalance Zone - The Legal Advocate
Jyong Biotech Ltd. (MENS) Gains 3.37% as Technical Support Holds, Resistance in FocusIV Rank - Newser
Jyong Biotech Ltd. (MENS) Stabilizes Near Key Support After Modest UptickIchimoku TK Cross - Newser
Jyong Biotech Ltd Azioni (MENS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):